Our patient-focused publication on young-onset lung cancer is now published in @JAMAOnc. To every patient told they were ‘too young’ for lung cancer, and to the families who stood beside them, this is for you 🤍. @MDAndersonNews https://t.co/kT9ZmKOBCe

Sequencing, tough cases, and tips you’ll actually use Monday morning. Join moderator Dr. @benlevylungdoc and panelists Drs. David Carbone, @MillieDas1, @MattGubensMD, Kartik Konduri, Laura Macke, @RachelSanbornMD, and @lungoncdoc for this case-driven masterclass on Advanced

I love being an oncologist and I love advocating for this community, but I hate lung cancer. Losing incredible people like Angus, who poured SO MUCH strength and hope into this community, is the hardest part of this work. We miss you, my dear friend. Your impact lives on. 🤍

New in @JCO_ASCO CHRYSALIS-2 Cohort C shows amivantamab + lazertinib delivers meaningful and durable activity in atypical EGFR-mutated NSCLC (G719X, L861Q, S768I). ORR 52% overall, 57% in 1L, and IMPRESSIVE mPFS up to 19.5 months with no new safety signals. A real step forward

LIVE from #NACLC25 | NSCLC Game Plan: Navigating HER2 with Evidence & Insight

AI is reshaping energy demand, and we’re ready. Our Chairman & CEO Mike Wirth shares how we’re powering the future.

What an exciting few days in Chicago! Thank you to all who attended the IASLC @ASCO #NACLC2025! From early detection and biomarker research to surgical, radiation, and treatment innovations, the past few days showcased meaningful progress in #lungcancer care.

Grateful to present an update on the phase II eNRGy trial at #NACLC25: zenocutuzumab in pts with treatment-naive, NRG1-fusion positive NSCLC. Zenocutuzumab was FDA approved December 2024 in previously treated NSCLC and pancreatic cancer but did include some treatment naive.

Proud mentor moment! Our team’s single-institution study on young-onset lung cancer was presented at #NACLC25. Grateful for these incredible colleagues who share a commitment to advancing care for this pt population. More to come, stay tuned! @MDAndersonNews @maraantonoff

@DrewMoghanaki Thank you - finally put something together. Here’s my current version. Curious if this looks ok for a patient-centered audience (topic = metastatic NSCLC). Trying to minimize text and lean heavily on visuals. #radonc @EvanThomas84 @nbn426 @gwalls89 @lungoncdoc

Our Holiday Gift Guide for the anime and manga fan in your life is here!

This morning we presented some results from the BREATHE study ➡️35% of respondants experienced severe burnout by MBI ➡️ close to 50% had self reported symptoms of burnout ➡️ Over 80% still had a high sense of personal accomplishment @lungoncdoc @drshieldsmd @ipreeshagul

Join us live on X from #NACLC25 tonight at 8:30 PM CST for our lung cancer #IDEOXchange discussing the latest developments with Drs. @ChristineBestv1 @theabzlab @lungoncdoc @GavittWoodard @marinagarassino @ajuloorimd @NarjustFlorezMD @hjrossmd @dramycummings @hari_keshava

Robust multidisciplinary discussion of oligometastatic NSCLC at #NACLC25 with Drs. @dwightowenmd @maraantonoff @CJTsaiMDPhD and @jillfeldman4. Impressive data but key is patient selection. When does local consolidation add benefit and when does it only add risk?

High rates of burnout among early-career thoracic oncology faculty were just presented at #NACLC2025—this isn’t a personal failure, it’s a systemic problem. Long hours, emotional load, and constant pressure are taking a toll. @ASridharMD @AnaVManana @IASLC

Ep 2 of Nationwide Amplified: Talaat McNeely, CEO of His & Her Money, shares how he went from drowning in debt to building a marriage of trust, hitting financial goals, & helping others do the same.

Surgery vs SBRT #NACLC25 “In the surgical literature the rates of nodal upstaging are never zero.” @BTongMD This point alone to me (identifying pts with more advanced disease who may benefit from systemic therapy) will always make surgery preferable to SBRT in operable pts.

Dear friend & colleague @maraantonoff shares her expertise on the evolving role of surgery in stage 4 disease. #NACLC25 @IASLC

Lively debate #NACLC25 between @BrunaPellini and @meerapatelmd about perioperative immunotherapy with @ErinGillaspie moderating. Final vote: neoadjuvant only for pCR Perioperative for everyone else. …and surgery is still the main event!!! 😷

Great to unpack the evolving EGFR landscape with such insightful colleagues & friends here at #NACLC25. @EddieSantosMD @JSabari @AlexSpiraMDPhD @IASLC

You’ve got options when it comes to trading. Discover how Cboe Index Options can support your strategies with flexible solutions to meet your goals.

Channeling a @UTAustin-style playbook, Dr. @meerapatelmd uses a football analogy to unpack perioperative therapy in early-stage NSCLC for our patients! So good! #NACLC25 @IASLC

Great debates at #NACLC25 are underway! Thrilled to see my dear friend & Miami Cancer Institute’s NEWEST thoracic oncology lead, Dr. @BrunaPellini, deliver an elegant presentation on risk-adapted management for early-stage resectable NSCLC.

Our BREATHE study highlights unique thoracic oncology pressures: 📈 Rapidly evolving treatments, late diagnoses, high mortality & patient volume all fuel burnout. 📊 62% keep up with emerging data regularly, yet 30+% struggle to keep pace. Grateful to our study team. #NACLC25

So proud of @ASridharMD sharing results from our BREATHE study: the first to characterize burnout in early-career thoracic oncologists. 🔥 >1 in 3 early-career oncologists affected 💡 Marriage, sleep & family responsibility appear to be protective @IASLC #NACLC25

You may not know it's there, but Fusarium ear rot can hit your yield & crop quality hard. 🌽 Hear tips from Tyler Harp on how to protect your corn with Miravis Neo.